YHYukiko Hayashi

Yukiko Hayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yukiko Hayashi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AB007. OA01.07: CD70 in thymic carcinoma: a promising diagnostic marker

    by Jumpei Kashima, Tsunekazu Hishima, Yusuke Okuma, Masumi Ogawa, Yukiko Hayashi, Shin-Ichro Horiguchi, Akiko Tonooka, Toru Motoi, Hirotoshi Horio

    Background: CD70, one of tumor necrosis factor family protein, is reported to be expressed in a large spectrum of solid tumors and hematological malignancies. CD70 is an attractive target for antibody-based therapy and several clinical trials targeting CD70 are being conducted. We previously demonstrated CD70 expression was frequently observed on neoplastic epithelial cells of thymic squamous cell carcinoma (TSCC) via immunohistochemistry (IHC) with antibody for frozen section in the limited number of samples. There have been no reports of CD70 expression focusing on formalin fixed paraffin embedded (FFPE) thymic tumors. In this study, we investigated the utility of a CD70 antibody applied on routine FFPE tissues by assessing a larger number of thymic epithelial tumors, thymic carcinoids and lung squamous cell carcinomas (LSCCs). Methods: FFPE tissues of TSCC (operative specimens: n=34, biopsy specimens: n=11), thymoma (n=59), thymic carcinoid (n=3), and LSCC (n=30) obtained in a single institution were immunohistochemically analyzed with anti-CD70 antibody (TNFSF7, clone 301731, R&B systems) Immunoreactivity for CD70 were semi-quantitatively scored according to the proportion of positive cells. IHC of CD5 and CD117 was also performed. We compared mRNA level of CD70 from frozen tissues of TSCC (n=12) and certain subtypes of thymoma with little lymphocyte infiltration (type A: n=4, type B3: n=6) by quantitative real-time polymerase chain reaction (RT-PCR). Results: Seventy-nine percent (27/34) of TSCC cases were positive for CD70, meanwhile all thymoma including type B3 and thymic carcinoid cases were negative. Twenty percent (6/30) of LSCC cases were positive for CD70, but it was significantly lower than TSCC cases (PConclusions: CD70 immunohistochemistry with a paraffin section-reactive antibody is useful in distinguishing TSCC from histological mimickers such as type B3 thymoma and LSCC. TSCC may also be a promising candidate for immunotherapy targeting CD70.


    • 1 June 2010
      • Vol. 57  (2) , 155-63

    HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.

    by Shin-Ichiro Horiguchi, Tsunekazu Hishima, Yukiko Hayashi, Yumiko Shiozawa, Kazumi Horiguchi, Katsumasa Kuroi, Masakazu Toi, Nobuaki Funata, Yoshinobu Eishi

    HER2 oncoprotein plays an essential role in breast cancer growth and differentiation. Determination of HER2 status contributes not only to predicting survival but also to selecting the patients for anti-HER2 therapy. HER2 protein expressed in human cancer cells often contains variant forms as well as the full-length wild-type form. In the present study, we investigated the subcellular localization of HER2 protein in 1053 primary breast cancer tissues. HER2 protein was stained by various immunohistochemical methods and studied by immunoelectron microscopy to confirm the intracellular localization. Thirty-four of 1053 specimens showed cytoplasmic staining of the intracellular domain of HER2 protein by the HercepTest and CB-11. In contrast, no immunoreactivity to the antibodies against the extracellular domain was observed. None of the 34 specimens showed amplification of the HER2 protein by fluorescence in situ hybridization. Subsequently, we studied the association of the cytoplasmic expression of HER2 with neuroendocrine differentiation. Interestingly, all 34 specimens had some positive signals of neuroendocrine markers such as synaptophysin, chromogranin A, neuron-specific enolase, and CD56. Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation.


    • 1 June 2010
      • Vol. 57  (2) , 165-75

    Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients.

    by Kazumi Horiguchi, Masakazu Toi, Shin-Ichiro Horiguchi, Masahiro Sugimoto, Yasuhiro Naito, Yukiko Hayashi, Takayuki Ueno, Shinji Ohno, Nobuaki Funata, Katsumasa Kuroi, et al.

    We investigated the significance of CD24 and CD44 expression for predicting responses to chemotherapy and prognosis in primary breast cancer patients. Diagnosis of breast cancer was confirmed by core needle biopsy, and immunohistochemical studies were performed. Preoperatively, patients received anthracycline-containing chemotherapy. Expression of CD44 and CD24 was assessed immunohistochemically and the relationship with chemotherapy response and with prognosis was analyzed. Between 2001 and 2004, 139 women were enrolled in this study. In the correlation analysis, CD24 expression was negatively associated with pathological response to chemotherapy (p = 0.0003). A machine learning technique with an alternating decision tree (ADTree) showed that four logical rules are involved in predicting the response depending on the combination of CD24, HER2, tumor stage, CD44, progesterone receptor, and patient age. In the survival analysis, patients having CD44 (++) showed a significantly favorable prognosis as compared with others (p = 0.0002). A multivariate analysis showed that CD44 expression had an independent prognostic value (p < .0001). We found a significant correlation between CD44 expression and prognosis and between CD24 expression and response to chemotherapy. CD24 and CD44 expressions would be useful predictive markers, although further studies are needed.


    • 10 November 2004
      • Vol. 5  (6) , 480-3

    Discrepancy between pancreatographic and histopathological findings in the ventral pancreas of pancreas divisum.

    by Terumi Kamisawa, Shin-Ichirou Horiguchi, Yukiko Hayashi, Nobuaki Funata

    Pancreas divisum is a congenital anomaly in which the ventral and dorsal pancreatic ducts do not communicate. Autopsy case of pancreas divisum with a history of heavy consumption of alcohol was presented. Pancreatography via the major duodenal papilla showed a short ventral pancreatic duct of 1 cm in length, and hypoplasia of the ventral pancreas was suspected. As large cysts were confined to the dorsal pancreas, isolated dorsal pancreatitis was also suspected. At autopsy, extensive fibrosis was detected in both the ventral and dorsal pancreas. Immunohistochemical examination revealed that PP-rich islets were scattered in the fibrotic area between the ventral pancreatic parenchyma and the neck of the pancreas, suggesting that this fibrotic area originated from the ventral pancreas. These facts suggest that the short ventral pancreatic duct was not induced by hypoplasia of the ventral pancreas but was shortened secondarily by the alcohol-induced fibrosis. In pancreas divisum, a short ventral pancreatic duct resulting from secondary factors may be confused with that originating from hypoplasia of the ventral pancreas.

  • Endocrine component in ampullary carcinoma in relation to clinicopathological factors

    by Terumi Kamisawa, Yukiko Hayashi, Nobuaki Funata, Shinichirou Horiguchi, Toshikazu Yamaguchi

  • Polymerase chain reaction screening of immunoglobulin heavy chain and T cell receptor γ gene rearrangements: A practical approach to molecular DNA analysis of non‐Hodgkin’s lymphoma in a surgical pathology laboratory

    by Yukiko Hayashi, Masashi Fukayama, Nobuaki Funata, Tsunekazu Hishima, Takayo Oba, Morio Koike

    Characterization of the clonality of non‐Hodgkin’s lymphoma (NHL) by the rearranged segments of immunoglobulin heavy chain (IgH) or T cell receptor (TCR) genes is not only useful in the confirmation of the diagnosis but also for the future assessment of how a secondary lymphoma, such as a recurrence or another primary lymphoma, occurs. As a practical approach to obtaining and registering this information in a surgical pathology laboratory, FR3 and FR1 regions of IgH gene and TCRγ gene were concurrently amplified by polymerase chain reaction (PCR) using each pair of consensus primers and the same PCR protocol. Examined samples consisted of 134 primary NHL (phenotypically, 108 B cell and 26 T cell NHL), 19 reactive lymphadenopathies, as well as five secondary lymphomas whose primary lesions were included in this study. Among the primary NHL, the combined PCR analysis disclosed the clonality in 103 of 134 NHL (77%), by FR3 PCR in 77 B cell and two T cell NHL, by FR1 PCR in 59 B cell and one T cell NHL, and by TCRγ PCR in 11 B cell and 17 of 26 T cell NHL, but in none of the reactive lymphadenopathies. Among the secondary lymphomas, the same pattern of PCR analysis was obtained in two cases (the durations between first and second lymphomas; 6 and 10 months), which suggested recurrence. In contrast, different results were obtained in three cases (17–37 months), which indicated another primary or emergence of the subclones. The results of Southern blot analysis were concordant with the PCR results of the first and the secondary lymphomas. Although the combined PCR analysis cannot replace Southern blot hybridization because of its lower detection rate, it can select those cases suitable for further Southern blot analysis thus reducing the number of unnecessary examinations by nearly 75%. This approach may also be useful in the comparative evaluation of primary and secondary lymphomas.